Rash · children diagnosed with Kawasaki disease
It is very uncertain whether TNF‐α blockers intervention changes adverse effects after treatment initiation: cutaneous reactions (rash) compared with placebo or additional treatment (very low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes adverse effects: EPS: akathisia measured by average ESRS change scores compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term · patients with schizophrenia
It is very uncertain whether PERPHENAZINE changes adverse events: extrapyramidal adverse effects ‐ dystonia ‐ short term compared with PLACEBO (very low certainty).
1 finding from 1 review
Frequency of adverse effects ‐ dizziness ( · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher adverse effects: dizzinessNumber of participants experiencing… compared with placebo (moderate certainty).
1 finding from 1 review
Secondary outcome: all adverse events · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
Topical vitamin D derivative showed no clear difference in proportion of participants with adverse effects ‐ measured over 8… compared with placebo (moderate certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
1 finding from 1 review
Adverse effect/event: clinically important extrapyramidal adverse events ‐ akathisia (medium term) · schizophrenia
Mirtazapine adjunct may leads to lower adverse effects: extrapyramidal ‐ clinically important change… compared with placebo adjunct (low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate changes proportion of participants with adverse effects ‐ measured over 12… compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
It is very uncertain whether etretinate with PUVA therapy as co‐intervention changes proportion of participants with adverse effects ‐ measured over 20… compared with placebo with PUVA therapy (very low certainty).
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
Alitretinoin showed no clear difference in proportion of participants with adverse effects ‐ measured over 24… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effect: no clinically significant extrapyramidal adverse effects · patients with antipsychotic‐induced tardive dyskinesia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects or other adverse events · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: side effects‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
1 finding from 1 review
Somnolence · people with drug‐resistant focal epilepsy
Gabapentin probably leads to higher adverse effects: somnolenceNumber of participants experiencing… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: EPS: parkinsonism measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: parkinsonism measured by average ESRS change… compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).
1 finding from 1 review
Adverse effects/events ‐ extrapyramidal symptoms ‐ medium term Number of instances of extrapyramidal symptoms · delirious patients
It is very uncertain whether antipsychotics changes adverse Effects ‐ EPS Extrapyramidal Symptom Rating Scale, or not… compared with nonantipsychotics or placebo (very low certainty).
1 finding from 1 review
Proportion of patients with adverse effects№ of participants: 819(12 RCTs) · patients with symptoms of vertigo
Betahistine showed no clear difference in proportion of patients with adverse effects№ of participants: 819(12… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: 5 most common adverse effects (any age) – accidental injury · people with drug‐resistant focal epilepsy
Levetiracetam showed no clear difference in adverse effects: 5 most common adverse effects (any age) –… compared with placebo (low certainty).
1 finding from 1 review